KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Co-Diagnostics (CODX) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to 4076.22%.

  • Co-Diagnostics' EBITDA Margin fell 25696400.0% to 4076.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 6397.99%, marking a year-over-year decrease of 58312900.0%. This contributed to the annual value of 954.42% for FY2024, which is 4335900.0% down from last year.
  • As of Q3 2025, Co-Diagnostics' EBITDA Margin stood at 4076.22%, which was down 25696400.0% from 4865.69% recorded in Q2 2025.
  • Co-Diagnostics' 5-year EBITDA Margin high stood at 51.61% for Q1 2021, and its period low was 15158.15% during Q1 2025.
  • Its 5-year average for EBITDA Margin is 2245.81%, with a median of 425.93% in 2023.
  • Per our database at Business Quant, Co-Diagnostics' EBITDA Margin soared by 41740100bps in 2024 and then plummeted by -131848400bps in 2025.
  • Quarter analysis of 5 years shows Co-Diagnostics' EBITDA Margin stood at 50.53% in 2021, then crashed by -3152bps to 1542.11% in 2022, then skyrocketed by 72bps to 425.93% in 2023, then tumbled by -1633bps to 7380.62% in 2024, then surged by 45bps to 4076.22% in 2025.
  • Its EBITDA Margin was 4076.22% in Q3 2025, compared to 4865.69% in Q2 2025 and 15158.15% in Q1 2025.